Yan JIN

Dr. Yan JIN

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2024 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
BGBaocheng Gong
Baocheng Gong
TQTongyuan Qu
Tongyuan Qu
JZJiaojiao Zhang
Jiaojiao Zhang
YJYubin Jia
Yubin Jia
ZSZian Song
Zian Song
QZQiang Zhao
Qiang Zhao
Neuroblastoma (NB) is the most prevalent extracranial solid tumor in pediatric patients, and its treatment failure often associated with metastasis. In this study, LASSO, SVM-RFE, and random forest tree algorithms, was used to identify the pivotal gene involved in NB metastasis. NB cell lines (SK-N-AS and SK-N-BE2), in conjunction with NB tissue were used for further study. ABLIM3 was identified as the hub gene and can be an independent prognostic factor for patients with NB. The immunohistochemical analysis revealed that ABLIM3 is negatively correlated with the metastasis of NB. Patients with low expression of ABLIM3 had a poor prognosis. High ABLIM3 expression correlated with APC co-stimulation and Type1 IFN response, and TIDE analysis indicated that patients with low ABLIM3 expression exhibited enhanced responses to immunotherapy. Downregulation of ABLIM3 by shRNA transfection increased the migration and invasion ability of NB cells. Gene Set Enrichment Analysis (GSEA) revealed that genes associated with ABLIM3 were primarily enriched in the cell adhesion molecules (CAMs) pathway. RT-qPCR and western blot analyses demonstrated that downregulation of ABLIM3 led to decreased expression of ITGA3, ITGA8, and KRT19, the key components of CAMs. This study indicated that ABLIM3 can be an independent prognostic factor for NB patients, and CAMs may mediate the effect of ABLIM3 on the metastasis of NB, suggesting that ABLIM3 is a potential therapeutic target for NB metastasis, which provides a novel strategy for future research and treatment strategies for NB patients.

23 March 2022 in British Journal of Radiology
Verified
Journal Article
Closed access
ZWZixuan Wei
Zixuan Wei
JLJie Li
Jie Li
YJYan JIN
Yan JIN
YLYun Liu
Yun Liu
PWPeiguo Wang
Peiguo Wang
QZQiang Zhao
Qiang Zhao
Objective: To retrospectively analyze radiotherapy (RT) regimens for patients with high-risk neuroblastoma (HRNB) at the primary site after surgery, and to further analyze the characteristics of patients who would benefit more from RT. Methods: 98 pediatric patients with HRNB were analyzed for local control (LC), RT dose, extent of excision and prognostic factors. Among them, 69 children received RT. Results: The 3 year LC rates were 96.9 and 62.1% (p < 0.001) in the RT and non-RT groups, respectively. In the non-RT group, LC was better in patients with complete macroscopic resection (CME) than in those with incomplete macroscopic resection (IME) (p = 0.026), while in the RT group, no significant difference in LC was found (p = 0.985). Among patients with IME, the LC was 100% in patients with RT doses >= 36 Gy and 66.7% in patients with doses <36 Gy. Conclusion: RT is valuable, provides patients with excellent LC, and is safe in the short term. RT had a complementary therapeutic effect on incompletely resected tumors, thus bringing their LC to the level of patients with CME. For patients with IME, RT at a dose of not less than 36 Gy may improve LC. Advances in knowledge: This study analysed the role of radiotherapy in HRNB, investigated the dose of RT depending on the degree of resection, and explored the characteristics of patients who would benefit more from RT.

10 July 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ZSZian Song
Zian Song
BGBaocheng Gong
Baocheng Gong
TQTongyuan Qu
Tongyuan Qu
YCYankun Chen
Yankun Chen
GZGuangzong Zhao
Guangzong Zhao
QZQiang Zhao
Qiang Zhao
Rhabdomyosarcoma (RMS) is one of the most common soft tissue sarcomas in children and adolescents, in which PAX3-FOXO1 fusion gene positive patients have very poor prognosis. PAX3-FOXO1 has been identified as an independent prognostic predictor in RMS, with no currently available targeted therapeutic intervention. The novel tyrosine kinase inhibitor anlotinib exhibits a wide range of anticancer effects in multiple types of cancers; however, there have been no relevant studies regarding its application in RMS. We investigated the effects of PAX3-FOXO1 on the therapeutic efficacy of anlotinib using the CCK-8 assay, flow cytometry, invasion assay, wound healing assay, western blotting, quantitative polymerase chain reaction(qPCR), and xenograft experiments. RNA-seq and co-immunoprecipitation assays were conducted to determine the specific mechanism by which anlotinib regulates PAX3-FOXO1 expression. Anlotinib effectively inhibited RMS cell proliferation and promoted apoptosis and G2/M phase arrest while impeding tumor growth in vivo. Downregulation of PAX3-FOXO1 enhances the antitumor effects of anlotinib. Anlotinib upregulates protein kinase NEK2 and increases the degradation of PAX3-FOXO1 via the ubiquitin-proteasome pathway, leading to a reduction in PAX3-FOXO1 protein levels. Anlotinib effectively inhibited the malignant progression of RMS and promoted degradation of the fusion protein PAX3-FOXO1. Anlotinib could be a targeted therapeutic approach to treat PAX3-FOXO1 fusion-positive RMS.

26 October 2024 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Closed access
BGBaocheng Gong
Baocheng Gong
TQTongyuan Qu
Tongyuan Qu
JZJiaojiao Zhang
Jiaojiao Zhang
YJYubin Jia
Yubin Jia
ZSZian Song
Zian Song
QZQiang Zhao
Qiang Zhao
[This corrects the article DOI: 10.1016/j.csbj.2024.04.024.].

1 February 2026 in Translational Pediatrics
Verified
Journal Article
Open access
XLXiaoying Li
Xiaoying Li
BGBaocheng Gong
Baocheng Gong
TQTongyuan Qu
Tongyuan Qu
YJYan JIN
Yan JIN
CCChong Chen
Chong Chen
QZQiang Zhao
Qiang Zhao
Neuroblastoma (NB) is recognized as the predominant extracranial malignant solid tumor in children and adolescent; the prognosis for high-risk patients remains poor. This limitation stems from its low mutational burden, an absence of antigen-presenting molecules, and vascular irregularities, which collectively impede immune cell infiltration, characterizing NB as a prototypical “cold tumor”. Intriguingly, metabolic pathways, especially through a novel glucose-dependent cellular death mechanism termed disulfidptosis and fatty acid metabolism (FAM), are pivotal in modulating the tumor’s energy dynamics and activating the tumor microenvironment (TME). Therefore, this study aims to explore the prognostic value and immunological implications of disulfidptosis-related fatty acid metabolism (DFAM) within the NB TME. To elucidate the implications of DFAM within the NB TME, this research included 971 NB patients. By using weighted gene co-expression network analysis (WGCNA), we constructed a prognostic risk score model based on DFAM, aimed at enhancing prognostication accuracy and informing therapeutic choices. The biological role of TFAP2D was validated in SK-N-AS and SK-N-BE2 cells via Cell Counting Kit-8 (CCK-8) assay, wound healing, and Transwell. Two distinct novel molecular subtypes were identified, revealing the correlations between DFAM and clinical-pathological features, prognostic outcomes, and TME infiltration patterns. The DFAM risk score model was established as an independent prognostic factor, correlated with immune cell infiltration and immunotherapeutic response. A novel discovery was the inhibitory effect of TFAP2D downregulation in NB cells on cellular survival, migration, and invasion. This research demonstrates that the crosstalk between DFAM and immune cells plays an important role in forming the “cold” TME of NB. The construction of DFAM-related score and the identification of a novel molecular subtype significantly contribute to the evolution of immunotherapeutic strategies. Furthermore, the discovery of TFAP2D as a metabolic driver of tumor progression provides a potential target to disrupt the metabolic plasticity of high-risk NB.

14 May 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ZSZian Song
Zian Song
BGBaocheng Gong
Baocheng Gong
TQTongyuan Qu
Tongyuan Qu
YCYankun Chen
Yankun Chen
GZGuangzong Zhao
Guangzong Zhao
QZQiang Zhao
Qiang Zhao